134 related articles for article (PubMed ID: 9794202)
1. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.
Toda M; Rabkin SD; Martuza RL
Hum Gene Ther; 1998 Oct; 9(15):2177-85. PubMed ID: 9794202
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
3. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1.
Yazaki T; Manz HJ; Rabkin SD; Martuza RL
Cancer Res; 1995 Nov; 55(21):4752-6. PubMed ID: 7585498
[TBL] [Abstract][Full Text] [Related]
4. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.
Nakano K; Todo T; Chijiiwa K; Tanaka M
Mol Ther; 2001 Apr; 3(4):431-7. PubMed ID: 11319903
[TBL] [Abstract][Full Text] [Related]
6. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.
Walker JR; McGeagh KG; Sundaresan P; Jorgensen TJ; Rabkin SD; Martuza RL
Hum Gene Ther; 1999 Sep; 10(13):2237-43. PubMed ID: 10498254
[TBL] [Abstract][Full Text] [Related]
7. Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207.
Oyama M; Ohigashi T; Hoshi M; Murai M; Uyemura K; Yazaki T
J Urol; 2001 Apr; 165(4):1274-8. PubMed ID: 11257700
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.
Todo T; Rabkin SD; Chahlavi A; Martuza RL
Hum Gene Ther; 1999 Nov; 10(17):2869-78. PubMed ID: 10584932
[TBL] [Abstract][Full Text] [Related]
9. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207.
Oyama M; Ohigashi T; Hoshi M; Murai M; Uyemura K; Yazaki T
Jpn J Cancer Res; 2000 Dec; 91(12):1339-44. PubMed ID: 11123435
[TBL] [Abstract][Full Text] [Related]
11. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice.
Sundaresan P; Hunter WD; Martuza RL; Rabkin SD
J Virol; 2000 Apr; 74(8):3832-41. PubMed ID: 10729157
[TBL] [Abstract][Full Text] [Related]
12. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
13. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.
Todo T; Feigenbaum F; Rabkin SD; Lakeman F; Newsome JT; Johnson PA; Mitchell E; Belliveau D; Ostrove JM; Martuza RL
Mol Ther; 2000 Dec; 2(6):588-95. PubMed ID: 11124059
[TBL] [Abstract][Full Text] [Related]
14. G207, modified herpes simplex virus type 1, kills human pancreatic cancer cells in vitro.
Lee JH; Federoff HJ; Schoeniger LO
J Gastrointest Surg; 1999; 3(2):127-31; discussion 132-3. PubMed ID: 10457334
[TBL] [Abstract][Full Text] [Related]
15. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
[TBL] [Abstract][Full Text] [Related]
16. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.
Blank SV; Rubin SC; Coukos G; Amin KM; Albelda SM; Molnar-Kimber KL
Hum Gene Ther; 2002 Mar; 13(5):627-39. PubMed ID: 11916486
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses.
McAuliffe PF; Jarnagin WR; Johnson P; Delman KA; Federoff H; Fong Y
J Gastrointest Surg; 2000; 4(6):580-8. PubMed ID: 11307092
[TBL] [Abstract][Full Text] [Related]
18. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207).
Carew JF; Kooby DA; Halterman MW; Federoff HJ; Fong Y
Hum Gene Ther; 1999 Jul; 10(10):1599-606. PubMed ID: 10428205
[TBL] [Abstract][Full Text] [Related]
19. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Nakano K; Todo T; Zhao G; Yamaguchi K; Kuroki S; Cohen JB; Glorioso JC; Tanaka M
J Gene Med; 2005 May; 7(5):638-48. PubMed ID: 15754306
[TBL] [Abstract][Full Text] [Related]
20. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer.
Jorgensen TJ; Katz S; Wittmack EK; Varghese S; Todo T; Rabkin SD; Martuza RL
Neoplasia; 2001; 3(5):451-6. PubMed ID: 11687957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
